DelveInsight’s “Thrombocytopenia Market“ report provides a thorough comprehension of the Thrombocytopenia, historical and forecasted epidemiology, and the Thrombocytopenia market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Thrombocytopenia market report also proffers an analysis of recent Thrombocytopenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs.
Some of the vital points from the Thrombocytopenia Market Research Report
For additional information on Market Impact by Therapies, visit: Thrombocytopenia Therapeutics Market Analysis
Thrombocytopenia is a condition in which the blood has a lower than a normal number of platelets. The condition can be inherited or acquired. Thrombocytopenia causes, sometimes, are not known. The main Thrombocytopenia symptoms include mild-to-severe bleeding. Bleeding can occur inside the body or underneath the skin, or from the skin’s surface. As per DelveInsight’s analysts, the total number of Thrombocytopenia cases in the 7MM was 1,653,934 in 2020. The Thrombocytopenia cases are expected to increase throughout the study period of 20192032 with a decent CAGR.
The Thrombocytopenia Market Report provides historical as well as forecasted epidemiological analysis segmented into:
Thrombocytopenia Emerging Therapies Along with Key Players
Thrombocytopenia pipeline possesses potential drugs in mid-stage developments to be approved soon. The major key players enumerated below can create a significant positive shift in Thrombocytopenia market size.
Thrombocytopenia Market Drivers
Thrombocytopenia Market Barriers
Scope of the Thrombocytopenia Market Insight
Request for a Webex demo of the report @ Thrombocytopenia Market Size Analysis
Table of Contents
1
Key Insights on Thrombocytopenia
2
Executive Summary of Thrombocytopenia
3
Thrombocytopenia Market Overview at a Glance
4
Disease Background and Overview: Thrombocytopenia
5
Thrombocytopenia Patient Journey
6
Thrombocytopenia Epidemiology and Patient Population
6.1
United States Epidemiology
6.2
EU5 Countries Epidemiology
6.2.1
Germany
6.2.2
France
6.2.3
Italy
6.2.4
Spain
6.2.5
United Kingdom
6.3
Japan Epidemiology
7
Thrombocytopenia Treatment
8
Thrombocytopenia Unmet Needs
9
Thrombocytopenia Marketed Drugs
9.1
Cablivi (Caplacizumab/ALX-0081): Sanofi (Ablynx)
9.2
Tavalisse (Fostamatinib): Rigel Pharmaceuticals/Kissei Pharmaceutical
9.3
Doptelet (Avatrombopag): Sobi (Dova Pharmaceuticals)
9.4
Mulpleta/Mulpleo (Lusutrombopag): Shionogi & Co., Ltd.
9.5
Nplate (Romiplostim, AMG-531): Amgen
9.6
Promacta (eltrombopag): Novartis
9.7
Rituxan (rituximab): Zenyaku Kogyo
10
Thrombocytopenia Emerging Drugs
10.1
Key Cross Competition
10.2
Rozanolixizumab (UCB7665): UCB Biopharma
10.3
Rilzabrutinib (PRN-1008): Principia Biopharma
10.4
TAK-755 (BAX930/SHP655): Baxalta/Takeda
10.5
Efgartigimod (ARGX-113): Argenx
10.6
GC5101B (GC5107A, IV-Globulin SN Inj. 10%): GC Pharma
10.7
Narsoplimab (OMS721): Omeros Corporation
10.8
BT-595: Biotest
10.9
TAK-079: Millennium Pharmaceuticals/Takeda
10.10
Thrombosomes: Cellphire
10.11
M254 (Hypersialylated IgG): Momenta Pharmaceuticals
10.12
BIVV020: Sanofi
10.13
Interleukin 2: ILTOO Pharma
10.14
SKI-O-703: Genosco (Subsidiary of Oscotec)
11
7MM Thrombocytopenia Market Analysis
12
United States Thrombocytopenia Market Outlook
13
EU-5 Thrombocytopenia Market Outlook
13.1
Germany Market Size
13.2
France Market Size
13.3
Italy Market Size
13.4
Spain Market Size
13.5
United Kingdom Market Size
14
Japan Thrombocytopenia Market Outlook
15
16
17
SWOT Analysis
18
Reimbursement and Thrombocytopenia Market Access
19
Appendix
20
DelveInsight Capabilities
21
Disclaimer
22
About DelveInsight
Browse detailed TOC with charts, figures, tables @ Thrombocytopenia Market Size Report
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/